Mengquan Li
- Co-authors
- Xu HanKeke MiaoLiuxing WangQingxia FanFeng WangYan SunWeijie ZhangJing Su
- Topics
- Cancer-related molecular mechanisms research (5 papers)Cancer Treatment and Pharmacology (3 papers)Breast Cancer Treatment Studies (3 papers)
In The Last Decade
Mengquan Li
19 papers receiving 506 citations
Peers
Comparison fields: 5 of 66
- Molecular Biology 390
- Cancer Research 297
- Oncology 89
- Immunology 35
- Pulmonary and Respiratory Medicine 33
Countries citing papers authored by Mengquan Li
This map shows the geographic impact of Mengquan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengquan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengquan Li more than expected).
Fields of papers citing papers by Mengquan Li
This network shows the impact of papers produced by Mengquan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengquan Li. The network helps show where Mengquan Li may publish in the future.
Co-authorship network of co-authors of Mengquan Li
This figure shows the co-authorship network connecting the top 25 collaborators of Mengquan Li. A scholar is included among the top collaborators of Mengquan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengquan Li. Mengquan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 9 | |
| 2 | 39 | |
| 3 | 29 | |
| 4 | 38 | |
| 5 | Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K/AKT signaling pathway. | 49 |
| 6 | 97 | |
| 7 | Silencing of the long non-coding RNA RHPN1-AS1 suppresses the epithelial-to-mesenchymal transition and inhibits breast cancer progression. | 17 |
| 8 | 4 | |
| 9 | 12 | |
| 10 | 1 | |
| 11 | 31 | |
| 12 | [Value of FOXP3 Tregs predicting the effectiveness of neoadjuvant chemotherapy in patients with breast cancer]. | 1 |
| 13 | 92 | |
| 14 | 17 | |
| 15 | [Effects of all trans retinoic acid on the expression alterations of beta-protein 1 in human breast cancer cell lines of MDA-MB-468 and MCF-7]. | 1 |
| 16 | [Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide]. | 2 |
| 17 | 54 | |
| 18 | 3 | |
| 19 | 17 | |
| 20 | 0 |
About Mengquan Li
Mengquan Li is a scholar working on Cancer Research, Toxicology and Oncology, having authored 20 papers that have together received 513 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (5 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (3 papers). The work is most often cited by research in Cancer Research (297 citations), Molecular Biology (390 citations) and Oncology (89 citations). Mengquan Li has collaborated with scholars based in China and Japan. Frequent co-authors include Xu Han, Keke Miao, Liuxing Wang, Qingxia Fan, Feng Wang, Yan Sun, Weijie Zhang, Jing Su, Xu Han and Jing Su. Their work appears in journals such as Journal of Clinical Oncology, Experimental Cell Research and Journal of Cellular Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.